新型荷尔蒙疗法与标准护理-基于mCRPC患者的A注册表比较有效性评估-患者
Paulina Jonéus1, Per Johansson1,2,3, Sophie Langenskiöld2,4
1Department of Statistics, Uppsala University, Uppsala, Sweden.
PloS one
|February 14, 2024
概括
新型抗雄激素药物 (NHT) 显示,与标准护理 (SoC) 相比,转移性割抗性前列腺癌 (mCRPC) 患者的死亡率增加了64%. 进一步分析表明,NHT不会降低死亡率,可能会增加与骨相关的事件.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 新型荷尔蒙疗法 (NHT) 与转移性割抗性前列腺癌 (mCRPC) 的标准护理 (SoC) 的有效性比较.
- 对于mCRPC治疗方法存在有限的比较研究.
研究的目的:
- 在mCRPC患者中评估NHT与SoC的比较有效性.
- 评估NHT对死亡率和骨相关事件 (SRE) 的影响.
主要方法:
- 在获得结果数据之前,研究设计和分析在协议中公布.
- 患者组在许多共同变量上得到平衡;未观察到的混因子通过安慰剂回归评估.
- 用于估计治疗对死亡率的影响的边界策略.
主要成果:
- 与SoC相比,在NHT患者中观察到64%的死亡率增加.
- 不能排除混杂是观察到的死亡率差异的原因.
- NHT不会降低死亡率;证据表明,NHT患者的SRE增加.
结论:
- 对于mCRPC的标准护理 (SoC) 经常涉及dcetaxel.
- 新型荷尔蒙疗法 (NHT) 没有对死亡率或SRE产生积极影响,而且成本更高.
- 需要进行进一步的比较研究,包括生活质量结果.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


